181 related articles for article (PubMed ID: 22215415)
1. Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis.
Han ZD; Zhang YQ; He HC; Dai QS; Qin GQ; Chen JH; Cai C; Fu X; Bi XC; Zhu JG; Liao DJ; Lu XP; Mo ZY; Zhu YP; Zhong WD
Med Oncol; 2012 Dec; 29(4):2877-88. PubMed ID: 22215415
[TBL] [Abstract][Full Text] [Related]
2. An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis.
Jiang FN; He HC; Zhang YQ; Yang DL; Huang JH; Zhu YX; Mo RJ; Chen G; Yang SB; Chen YR; Zhong WD; Zhou WL
PLoS One; 2013; 8(5):e63941. PubMed ID: 23737958
[TBL] [Abstract][Full Text] [Related]
3. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.
Ummanni R; Mundt F; Pospisil H; Venz S; Scharf C; Barett C; Fälth M; Köllermann J; Walther R; Schlomm T; Sauter G; Bokemeyer C; Sültmann H; Schuppert A; Brümmendorf TH; Balabanov S
PLoS One; 2011 Feb; 6(2):e16833. PubMed ID: 21347291
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.
Zhou L; Xia D; Zhu J; Chen Y; Chen G; Mo R; Zeng Y; Dai Q; He H; Liang Y; Jiang F; Zhong W
Clin Transl Oncol; 2014 Oct; 16(10):906-13. PubMed ID: 24659377
[TBL] [Abstract][Full Text] [Related]
5. Identification of Differentially Expressed Proteins in the Serum of Colorectal Cancer Patients Using 2D-DIGE Proteomics Analysis.
Lim LC; Looi ML; Zakaria SZ; Sagap I; Rose IM; Chin SF; Jamal R
Pathol Oncol Res; 2016 Jan; 22(1):169-77. PubMed ID: 26463353
[TBL] [Abstract][Full Text] [Related]
6. Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer.
Davalieva K; Kostovska IM; Kiprijanovska S; Markoska K; Kubelka-Sabit K; Filipovski V; Stavridis S; Stankov O; Komina S; Petrusevska G; Polenakovic M
Prostate; 2015 Oct; 75(14):1586-600. PubMed ID: 26074449
[TBL] [Abstract][Full Text] [Related]
7. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
[TBL] [Abstract][Full Text] [Related]
8. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker.
Qian X; Li C; Pang B; Xue M; Wang J; Zhou J
PLoS One; 2012; 7(5):e37225. PubMed ID: 22615945
[TBL] [Abstract][Full Text] [Related]
9. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
[TBL] [Abstract][Full Text] [Related]
10. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
[TBL] [Abstract][Full Text] [Related]
11. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
12. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
Fang E; Zhang X; Wang Q; Wang D
Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
[TBL] [Abstract][Full Text] [Related]
13. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues.
Sun W; Xing B; Sun Y; Du X; Lu M; Hao C; Lu Z; Mi W; Wu S; Wei H; Gao X; Zhu Y; Jiang Y; Qian X; He F
Mol Cell Proteomics; 2007 Oct; 6(10):1798-808. PubMed ID: 17627933
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers.
Ummanni R; Duscharla D; Barett C; Venz S; Schlomm T; Heinzer H; Walther R; Bokemeyer C; Brümmendorf TH; Murthy PV; Balabanov S
J Proteomics; 2015 Apr; 119():218-29. PubMed ID: 25724726
[TBL] [Abstract][Full Text] [Related]
16. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
17. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis.
Lin JF; Xu J; Tian HY; Gao X; Chen QX; Gu Q; Xu GJ; Song JD; Zhao FK
Int J Cancer; 2007 Dec; 121(12):2596-605. PubMed ID: 17722004
[TBL] [Abstract][Full Text] [Related]
18. Silencing of hepsin and inosine 5-monophosphate dehydrogenase 2 by siRNA reduces prostate cancer cells proliferation.
A Wahab N; D Dardar H; Yunus R; M Zainudin Z; M Mokhtar N
Malays J Pathol; 2022 Apr; 44(1):29-38. PubMed ID: 35484884
[TBL] [Abstract][Full Text] [Related]
19. Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers.
Zhang M; Chen L; Yuan Z; Yang Z; Li Y; Shan L; Yin B; Fei X; Miao J; Song Y
Discov Med; 2016 Nov; 22(122):281-295. PubMed ID: 28009970
[TBL] [Abstract][Full Text] [Related]
20. Quantitative proteomic study of human prostate cancer cells with different metastatic potentials.
Li Q; Li Y; Wang Y; Cui Z; Gong L; Qu Z; Zhong Y; Zhou J; Zhou Y; Gao Y; Li Y
Int J Oncol; 2016 Apr; 48(4):1437-46. PubMed ID: 26846621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
